<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317159</url>
  </required_header>
  <id_info>
    <org_study_id>IMAGE-201</org_study_id>
    <nct_id>NCT02317159</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia</brief_title>
  <official_title>Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cttq</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in
      patients with chronic phase of Chronic Myeloid Leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major molecular response</measure>
    <time_frame>2 years</time_frame>
    <description>the rate of major molecular response in two years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete cytogenetics response</measure>
    <time_frame>1 years</time_frame>
    <description>the rate of complete cytogenetics response in one years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>over survival</measure>
    <time_frame>2 years</time_frame>
    <description>the rate of over survival in two years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progress free survival</measure>
    <time_frame>2 years</time_frame>
    <description>the rate of progress free survival in two years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>imatinib，Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg imatinib qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>400mg imatinib qd PO</description>
    <arm_group_label>imatinib，Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18；

          -  The new diagnosis of CML patients in six months；

          -  No proof of extra-medullary infiltration of leukemia；

          -  ECOG PS score：0-2；

          -  Hepatic and renal functions are normal，Serum bilirubin≤1.5*ULN, serum ALT and
             AST≤2.5*ULN, serum Cr≤1.5*ULN;

          -  Do not receive the treatment of anti-CML；

          -  Subjects signed informed consent form in line with GCP requirements。

        Exclusion Criteria:

          -  Pregnant or lactating women；

          -  Received TKIs any time before；

          -  Failure to control systemic infection or multiple organ failure；

          -  According to the investigator's judgment, there are concomitant diseases with a
             serious safety hazard or affect the patients completed the study；

          -  Being diagnosed with other malignancies in the prior 12 months；

          -  Have a history of neurological or psychiatric disorders, including epilepsy or
             dementia；

          -  Known or suspected allergy to imatinib；

          -  BSA≤1.5m2；

          -  Using other experimental drugs or participating in other clinical trials in the prior
             one months。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhixiang Shen, Master</last_name>
    <phone>13901651262</phone>
  </overall_contact>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

